ArticleNews reportPHN-05052026-11-01 14:42 CT

As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround

Source · The American Journal of Managed Care® (AJMC®)

TLDR

AJMC reports that Andel and Novo Nordisk announced a collaboration allowing employers to contribute toward employees’ semaglutide costs outside insurance. The arrangement comes as a WTW survey found that 53% of employers cover GLP-1 drugs for weight loss, down from 57% in 2025.

01—Key points

01The companies say the arrangement covers injectable and oral semaglutide, with employers choosing their contribution.
02WTW found that 16% of employers currently cover these drugs but are considering removing coverage, up from 9% last year.
03Andel describes its program as a noninsurance model that lets employers reimburse part of employees’ out-of-pocket costs.

Why it matters Editorial

The collaboration illustrates a shift toward employer subsidies outside traditional insurance as companies narrow GLP-1 weight-loss coverage amid rising benefit costs.

Read the original at The American Journal of Managed Care® (AJMC®)↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.